Related Experiment Videos
[Phase II clinical study of a new anticancer drug boanmycin]
Objective:
To evaluate the efficacy of boanmycin (BAM) in patients with advanced cancers.
Methods:
A multicenter phase II clinical study on BAM was conducted on 105 cases received BAM as single agent, and 220 cases were treated with combination chemotherapy containing BAM.
Results:
The total response rate was 35.0% for single agent and 64.2% for combination chemotherapy group in advanced cancers. The response rate for single agent in malignant lymphoma, cancer of head and neck and breast cancer was 66.7%, 65.0% and 37.5%, respectively; and for combination chemotherapy group in malignant lymphoma, breast cancer, head and neck cancer, esophageal cancer and lung cancer was 88.5%, 62.5%, 50.0%, 47.2% and 45.8%, respectively. The main side effects with mild or moderate fever, chill, myalgia, gastrointestinal reactions, skin pigmentation as well as hardening of skin at injection site.
Conclusions:
BAM therapy was effective in malignant lymphoma, cancer of head and neck and other cancers.